Oral diclofenac combined with intra-portal pirarubicin: increased efficacy on liver VX2 tumour and hepatotoxicity in rabbits.
VX2 is a carcinoma established in rabbits and producing an autocrine growth factor, prostaglandin E2. Pirarubicin is a potent anti-VX2 agent. We investigated whether the oral intake of enprostil--a synthetic prostaglandin E2--or of diclofenac--a potent non-steroidal anti-inflammatory drug--increases the efficacy and decreases the hepatotoxicity of pirarubicin when injected in the portal trunk. Enprostil increased the number of hepatic tumoral nodules and induced hepatic alterations, especially venous dilatation. Paradoxically the combination of enprostil and pirarubicin was at least as effective as pirarubicin or diclofenac on VX2 cells. However, the toxicity was increased, especially with respect to sclerosing cholangitis. Diclofenac proved to be as effective as pirarubicin, and the addition of oral diclofenac to local pirarubicin injection increased its antitumoral effect (P < 0.02). However, the combination of diclofenac and pirarubicin was more toxic than pirarubicin alone and induced centrolobular necrosis and sclerosing cholangitis.
Donatini
B
B
Sandoz Clinical Development Centre, Camberley, Surrey, England.
Bognel
C
C
Munck
J N
JN
Ramirez
L
L
Ardouin
P
P
Rougier
P
P
D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D004008:Diclofenac / Q000008:administration & dosage*; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016620:Enprostil / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D008099:Liver / Q000187:drug effects*; D008113:Liver Neoplasms / Q000188:drug therapy*; D011168:Portal System; D011817:Rabbits
D000903:Antibiotics, Antineoplastic; D004008:Diclofenac; D004317:Doxorubicin; C027260:pirarubicin; D016620:Enprostil